Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. Its lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the c-Kit receptor, inhibiting signaling for mast cells and a maintenance signal for hematopoietic stem cells. KIT inhibition with briquilimab has demonstrated clinical outcomes both as a conditioning agent for stem cell transplant in SCID and Fanconi anemia. Its pipeline also includes KP-104 (vensobafusp alfa), a bifunctional complement inhibitor in clinical development, and KP-701, a preclinical B-cell receptor-targeted therapy.
Back to dashboard
Company Information
About this company
Key people
Thomas G. Wiggans
Executive Chairperson of the Board
Jeetinder Singh Mahal
President, Chief Executive Officer, Interim Principal Financial Officer, Director
Herb Cross
Chief Financial Officer, Corporate Secretary
Matthew E. Ros
Chief Operating Officer, Interim Corporate Secretary
Patrick J. Crutcher
Director
Judith Shizuru
Director
Svetlana Lucas
Independent Director
Kurt von Emster
Independent Director
Click to see more
Key facts
- Shares in issue33.27m
- EPICJSPR
- ISINUS4718712023
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$18.47m
- Employees22
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.